RecruitingNot ApplicableNCT05704530

Liquid Biopsies in Esophageal Cancer

Personalized Multimodal Treatment for Resectable Esophageal Cancer by Detecting Minimal Residual Disease Using Circulating Tumor DNA: a Multicentric Prospective Study

Sponsor

Universitaire Ziekenhuizen KU Leuven

Enrollment

248 participants

Start Date

Mar 29, 2023

Study Type

INTERVENTIONAL

Conditions

Esophageal Cancer

Summary

Purpose of this study is to determine the value of liquid biopsies, e.g. testing of minimal residual disease (MRD) by using liquid biopsies to measure circulating tumour DNA (ctDNA) at diagnosis and during the multimodal and multidisciplinary curative-intent treatment of resectable esophageal cancer.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is using liquid biopsies — blood tests that detect tumor DNA floating in the bloodstream — to better understand and monitor esophageal cancer (cancer of the food pipe). It aims to track how tumor genetics change throughout treatment and surgery. **You may be eligible if...** - You are over 18 years old - You have been newly diagnosed with esophageal cancer (either squamous cell carcinoma or adenocarcinoma), confirmed by pathology - Your cancer is localized or locally advanced (not yet spread to distant organs) - Your cancer is potentially resectable (removable with surgery) - You are eligible for multidisciplinary cancer treatment **You may NOT be eligible if...** - Your cancer has spread to distant sites (metastatic disease) - Your cancer type is not squamous cell carcinoma or adenocarcinoma - You have another active cancer - You have previously received chemotherapy or radiation before your current multidisciplinary assessment - Surgery is not planned as part of your treatment Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERBlood sample

Retrospective collection of leftover tissue from standard of care biopsies or resection specimens and prospective collection of additional blood samples for study-specific analyses at specific timepoints, at the same time as routine labs are foreseen. No additional venipunctures are expected.